Evogene (EVGN) Other financing activities (2013 - 2026)
Evogene (EVGN) posted Other financing activities of $101000.0 for Q1 2026, up 10200.0% sequentially from -$1000.0 in Q4 2025, and down 7.34% YoY from $109000.0 in Q1 2025.
Evogene (EVGN) Other financing activities (2013 - 2026) Analysis & Trends
Evogene has reported Other financing activities for 14 years, with the latest figure at $101000.0 in Q1 2026.
- Quarterly Other financing activities fell 7.34% year-over-year to $101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 228.69% YoY) and the FY2025 annual result came in at -$115000.0, down 238.55% from the prior year.
- Other financing activities rose to $101000.0 in Q1 2026 per EVGN's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $31.9 million in Q3 2022 and troughed at -$6.6 million in Q4 2023.
- A 5-year average of $9.3 million and a median of $104000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2023: Other financing activities soared 362150.0% in 2022, then plunged 742.86% in 2023.
- Over 5 years, Other financing activities stood at $29.0 million in 2022, then sank by 122.63% to -$6.6 million in 2023, then soared by 101.59% to $104000.0 in 2024, then slumped by 100.96% to -$1000.0 in 2025, then soared by 10200.0% to $101000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $101000.0, -$1000.0, and -$226000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101,000.00 |
| Mar 31, 2026 | 101,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -226,000.00 |
| Sep 30, 2025 | -226,000.00 |
| Jun 30, 2025 | 8.33 Mn |
| Jun 30, 2025 | 8.33 Mn |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 104,000.00 |
| Dec 31, 2024 | 104,000.00 |
| Sep 30, 2024 | -28,000.00 |
| Sep 30, 2024 | -28,000.00 |
| Dec 31, 2023 | -6.56 Mn |
| Dec 31, 2023 | -6.56 Mn |
| Sep 30, 2023 | 27.33 Mn |
| Sep 30, 2023 | 27.33 Mn |
| Jun 30, 2023 | 20.28 Mn |
| Jun 30, 2023 | 20.28 Mn |